Genericisation in cost-effectiveness analysis of cystic fibrosis medicines.

Beattie, Alice; Moore, Alex; Ramagopalan, Sreeram V

Beattie, Alice; Moore, Alex; Ramagopalan, Sreeram V.

Affiliation

Beattie A; Lane Clark & Peacock, London W1U 1DQ, UK.
Moore A; Lane Clark & Peacock, London W1U 1DQ, UK.
Ramagopalan SV; Lane Clark & Peacock, London W1U 1DQ, UK; Centre for Pharmaceutical Medicine Research, King's College London, London, UK. Electronic address: sreeram.ramagopalan@lcp.uk.com.

Lancet ; 403(10444): 2591-2592, 2024 Jun 15.

Article in En | MEDLINE | ID: mdl-38879249

Subject(s)

Cost-Benefit Analysis; Cystic Fibrosis; Drugs, Generic; Cystic Fibrosis/drug therapy; Cystic Fibrosis/economics; Humans; Drugs, Generic/economics; Aminophenols/economics; Aminophenols/therapeutic use; Benzodioxoles/economics; Benzodioxoles/therapeutic use; Quinolones/economics; Quinolones/therapeutic use; Drug Costs; Aminopyridines/economics; Aminopyridines/therapeutic use; Drug Combinations; Cost-Effectiveness Analysis

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Drugs, Generic / Cost-Benefit Analysis / Cystic Fibrosis Limits: Humans Language: En Journal: Lancet Year: 2024 Document type: Article Affiliation country: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google